European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population
In an usual regulatory shift, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) announced on Thursday that it will recommend approval of lecanemab (Leqembi; Eisai) as a treatment for symptoms associated with …